Evidence map›Paper›PMID 35860218›Full record

ArticlemedRxiv : the preprint server for health sciences2022

A comparison of four epidemic waves of COVID-19 in Malawi; an observational cohort study.

Catherine Anscombe, Samantha Lissauer, Herbert Thole, Jamie Rylance, Dingase Dula, Mavis Menyere, Belson Kutambe, Charlotte van der Veer, Tamara Phiri, Ndaziona P Banda and 15 more

Open access · greenAbstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 13 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 4 institutions in 3 countries.

Catherine AnscombeMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Samantha LissauerMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Herbert TholeMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Jamie RylanceMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Dingase DulaMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Mavis MenyereMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Belson KutambeMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Charlotte van der VeerMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Tamara PhiriDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Ndaziona P BandaKamuzu University of Health Sciences (formerly University of Malawi-College of Medicine) Blantyre, Malawi.
Kwazizira S MndoloDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Kelvin MpondaDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Chimota PhiriDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Jane MallewaKamuzu University of Health Sciences (formerly University of Malawi-College of Medicine) Blantyre, Malawi.
Mulinda NyirendaKamuzu University of Health Sciences (formerly University of Malawi-College of Medicine) Blantyre, Malawi.
Grace KathaDepartment of Medicine, Queen Elizabeth Central Hospital, Blantyre, Malawi.
Henry MwandumbaMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Stephen B GordonMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Kondwani C JamboMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Jennifer CornickMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Nicholas FeaseyMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Kayla G BarnesMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Ben MortonMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Philip M AshtonMalawi-Liverpool-Wellcome Clinical Research Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Blantyre COVID-19 Consortium
University of Liverpool · GBQueen Elizabeth Central Hospital · MWUniversity of Malawi · MWBroad Institute · US

Funding

Identifying genetic determinants of Rotavirus Vaccine Failure in Malawian ChildrenK01TW010853 · FIC · HARVARD SCHOOL OF PUBLIC HEALTH · PI BARNES, KAYLA G · 2018 to 2022
$731k
FIC NIH HHS K01 TW010853Medical Research Council MR/T008822/1Wellcome Trust
6 · The paper itself

Abstract

Background: Compared to the abundance of clinical and genomic information available on patients hospitalised with COVID-19 disease from high-income countries, there is a paucity of data from low-income countries. Our aim was to explore the relationship between viral lineage and patient outcome. Methods: We enrolled a prospective observational cohort of adult patients hospitalised with PCR-confirmed COVID-19 disease between July 2020 and March 2022 from Blantyre, Malawi, covering four waves of SARS-CoV-2 infections. Clinical and diagnostic data were collected using an adapted ISARIC clinical characterization protocol for COVID-19. SARS-CoV-2 isolates were sequenced using the MinIONâ"¢ in Blantyre. Results: We enrolled 314 patients, good quality sequencing data was available for 55 patients. The sequencing data showed that 8 of 11 participants recruited in wave one had B.1 infections, 6/6 in wave two had Beta, 25/26 in wave three had Delta and 11/12 in wave four had Omicron. Patients infected during the Delta and Omicron waves reported fewer underlying chronic conditions and a shorter time to presentation. Significantly fewer patients required oxygen (22.7% [17/75] vs. 58.6% [140/239], p<0.001) and steroids (38.7% [29/75] vs. 70.3% [167/239], p<0.001) in the Omicron wave compared with the other waves. Multivariable logistic-regression demonstrated a trend toward increased mortality in the Delta wave (OR 4.99 [95% CI 1.0-25.0 p=0.05) compared to the first wave of infection. Conclusions: Our data show that each wave of patients hospitalised with SARS-CoV-2 was infected with a distinct viral variant. The clinical data suggests that patients with severe COVID-19 disease were more likely to die during the Delta wave. Summary: We used genome sequencing to identify the variants of SARS-CoV-2 causing disease in Malawi, and found that each of the four waves was caused by a distinct variant. Clinical investigation suggested that the Delta wave had the highest mortality.

Identifiers

PMID35860218
PMCPMC9298135
OpenAlexW4213155951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.